How many years is the resistance period to osimertinib/osimertinib?

Osimertinib/osimertinib (Osimertinib) is a targeted therapy drug used to treat non-small cell lung cancer (NSCLC) with positive EGFR gene mutations. The drug resistance period varies depending on a variety of factors, and usually ranges from one to several years. The following are the main factors affecting the resistance period of osimertinib/osimertinib:

1.EGFRMutation type: The patient's EGFR mutation type plays an important role in the drug resistance period. For sensitive EGFR mutations, such as Del19 and L858R, osimertinib/Osimertinibusually has a long resistance period and can maintain effective treatment for a period of time; for drug-resistant mutations, such as T790Mmutation, osimertinib/osimertinib has a relatively short resistance period.

2.Speed of disease progression: The patient’s disease progression speed will also affect the length of the drug resistance period. Patients with rapid disease progression may develop drug resistance in a shorter period of time, and the drug resistance period is relatively short; while patients with slowly disease progression may be able to benefit from osimertinib treatment for a longer period of time, and the drug resistance period is relatively long.

3.Treatment history: The patient’s treatment history will also affect the length of the drug resistance period. For patients who have not received EGFR inhibitor treatment before, the resistance period of osimertinib/osimertinib may be relatively long; while for patients who have previously received EGFR inhibitor treatment, cross-resistance may occur, and the resistance period is relatively short.

4.Individual Differences: Each patient's biological characteristics and genomic variations are unique, and therefore response to and resistance to osimertinib/osimertinib will also vary. Some patients may have a longer period of resistance to osimertinib/osimertinib, while other patients may develop resistance within a short period of time.

Taken together, the resistance period of osimertinib/osimertinib usually ranges from one to several years, depending on the patient's EGFR mutation type, disease progression rate, treatment history, individual differences and other factors. However, with in-depth research on the mechanism of resistance and continuous improvement of treatment strategies, we can expect to be able to extend the resistance period of osimertinib/osimertinib in the future and improve the treatment effect and survival rate of patients.